CohBar to Present at Upcoming Investor and Scientific Conferences

Download as PDF

MENLO PARK, Calif.--(BUSINESS WIRE)-- CohBar, Inc. (OTCQX: CWBR and TSX-V: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics for diseases associated with aging, announced that management will be presenting at the following conferences:

  • Albion J. Fitzgerald, CohBar Chairman, will present at the GCFF Toronto Conference 2015 in Toronto on Saturday, September 26, 2015. Organized by NAI Interactive, the Global Chinese Financial Forum (GCFF) is the most prominent series of bi-lingual financial functions in both North America and China. Established in 2000, GCFF's mandate is to provide a world-class platform connecting both the Asian and North American financial markets.
  • Kenneth C. Cundy, Ph.D., CohBar Chief Scientific Officer, will present at the Boulder Peptide Symposium on Monday, September 28, 2015 during the Peptide Showcase session. The symposium brings together thought leaders in biotech, pharma, and academic institutions to present current paradigms in peptide therapeutics and to uncover solutions to challenges in peptide drug discovery and development.
  • Mr. Fitzgerald will also present at the OCTQX Life Sciences Virtual Investor Conference on Thursday, October 1, 2015 at 1:00 p.m. ET at www.VirtualInvestorConferences.com. The conference will feature live webcast presentations by senior executives from OTCQX-traded life science companies.

About CohBar

CohBar (OTCQX: CWBR and TSXV: COB.U) is the leader in the research and development of mitochondria-based therapeutics (MBTs), an emerging class of drugs for the treatment of diseases associated with aging. MBTs originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. This groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. MBTs offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.

For additional company information, please visit www.cohbar.com.

CohBar, Inc.
Jeff Biunno, CFO, 973-841-1233
jeff.biunno@cohbar.com
or
MacDougall Biomedical Communications
Heather Savelle, 781-235-3060
hsavelle@macbiocom.com

Source: CohBar, Inc.

Released September 23, 2015